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OVERVIEW 
Central sensitization refers to the amplification of pain by central nervous system mechanisms. 
Classically described as a consequence of ongoing nociceptive input, it is increasingly 
recognized that central sensitization also occurs independent of peripheral injury or 
inflammation. Features of central sensitization have been identified in nearly all chronic pain 
conditions, and it is considered the primary underlying cause of pain in conditions such as 
fibromyalgia. Central sensitization is characterized in these conditions by widespread pain and 
multisite hyperalgesia/allodynia. Co-occurring symptoms include fatigue, mood and cognitive 
problems, sleep disturbances, and multisensory hypersensitivity. Individuals with central 
sensitization often report previous exposure to psychosocial or physical stressors, and a higher 
personal lifetime and family history of pain, with the latter findings supported by genetic 
studies. Neuroimaging studies of central sensitization show evidence of: changes in brain gray 
matter in pain processing regions; neurochemical imbalances; and altered resting brain-
network connectivity between pro-nociceptive and antinociceptive brain areas. Immune system 
abnormalities have also been demonstrated in individuals with central sensitization. The 
recognition of central sensitization, and whether it is being driven by ongoing nociceptive input 
or it is occurring in the absence of a peripheral-driver, is critical for effective pain management. 
 
INTRODUCTION 
In this Special Issue of JABR, Woolf describes the first use of the term ͞central sensitization͟ as 
it relates to pain processing, as well as the early evolution of the meaning of this term.  
Described initially only in animal models, the term was first used by Woolf to refer: to a specific 
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spinal disorder mechanism that was responsible for augmenting ongoing peripheral nociceptive 
input (Woolf, 1983).  Other preclinical pain researchers subsequently identified additional 
spinal mechanisms that amplify nociceptive signaling.  The hallmarks of these processes were 
the presence of hyperalgesia and/or allodynia on quantitative sensory testing (QST) in animal 
models of nociception, often accompanied by enlargement of the nociceptive field and/or 
electrophysiological evidence of decreased firing threshold and increased discharge of spinal 
nociceptive neurons. Thus, the term central sensitization began to be used in a broader sense 
to convey the notion that an array of spinal mechanisms may be involved in amplifying or 
maintaining peripheral nociceptive input (Dougherty, Palecek, Paleckova, Sorkin, & Willis, 1992; 
Sluka & Westlund, 1992; Treede, Davis, Campbell, & Raja, 1992; Willis, 1988).  Even though a 
substantial body of research had begun to demonstrate the important role for supraspinal 
mechanisms in pain processing (Gebhart, 1986; T. S. Jensen & Yaksh, 1992; Willis, 1985; Yaksh, 
1988), in the 1980s and early 1990s the term central sensitization was originally applied: 1) only 
to situations where there was some initial ongoing peripheral nociceptive input; and 2) where 
the underlying mechanism(s) of this phenomenon was thought to lie in the spinal cord and 
dorsal root ganglion. 
 
In the mid-ϭ99Ϭ’s, ŵaŶǇ iŶǀestigators began to leverage the term and concept of central 
sensitization as a way of explaining the pain hypersensitivity observed in a number of chronic 
pain states in humans, including neuropathic pain (Gracely, Lynch, & Bennett, 1992; Persson, 
Axelsson, Hallin, & Gustafsson, 1995), fibromyalgia (FM) (Anderberg, 2000; Gibson, Littlejohn, 
Gorman, Helme, & Granges, 1994; Granges & Littlejohn, 1993; Kosek, Ekholm, & Hansson, 
1995; Sorensen, Bengtsson, Backman, Henriksson, & Bengtsson, 1995); headache (R. Jensen, 
Rasmussen, Pedersen, Lous, & Olesen, 1992; R. Jensen, Rasmussen, Pedersen, & Olesen, 1993); 
temporomandibular disorder (TMD) (Fillingim, Maixner, Kincaid, Sigurdsson, & Harris, 1996); 
and irritable bowel syndrome (IBS) (Mertz, Naliboff, Munakata, Niazi, & Mayer, 1995).  As with 
the animal models, the original technique used to identify central sensitization in humans was 
QST.  These early QST studies typically noted the same findings of secondary hyperalgesia or 
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allodynia seen in animal models of central sensitization, and this was used to infer that these 
same underlying processes may be playing a role in humans with these chronic pain conditions. 
 
More recently, newer techniques, such as functional, chemical, and structural brain imaging, 
EEG, and other research techniques, have been used to substantiate and further identify the 
presence of, and underlying mechanisms driving, central sensitization. Central sensitization has 
now been suggested to play a role in hundreds of painful and other medical conditions.  In fact, 
so much has been learned about the ubiquity of this problem in populations of chronic pain 
patients that there is now abroad consensus in the pain field that this might represent a third 
underlying core mechanism for pain, above and beyond nociceptive and neuropathic pain 
mechanisms that have been recognized for some time (C. Brummett et al., 2016; Kosek et al., 
2016). 
 
Chronic pain conditions that are now recognized mechanistically to fall within the spectrum of 
central sensitization include: FM; IBS (previously terŵed ͞spastiĐ Đolitis͟ uŶtil the recognition 
that there was little ͞–itis" and that motility changes were not the major pathological feature); 
TMD (previously termed temporomandibular joint syndrome until it was recognized the 
problem was largely outside the joint) (Bair, Brownstein, et al., 2013; Bair, Ohrbach, et al., 2013; 
Fillingim et al., 2011; Greenspan et al., 2013); and urinary chronic pelvic pain syndromes 
(where, again, the condition previously called interstitial cystitis is now called bladder pain 
syndrome) (Bagarinao et al., 2014; Clemens et al., 2014; Farmer et al., 2015).  This is not to say 
peripheral factors, or low-grade inflammation that is not identifiable clinically, do not play some 
role in these entities.  But it is relevant that clinicians who care for individuals with these 
conditions, and who are quite adept at identifying (with blood tests, imaging, or endoscopy) 
peripheral damage or inflammation, have generally concluded that these are not inflammatory 
or peripheral-based disorders.  A recent term, Chronic Overlapping Pain Conditions (COPCs), has 
been coined by the NIH to indicate that FM, IBS, chronic fatigue syndrome (CFS), headache, 
interstitial cystitis/bladder pain syndrome, TMD, endometriosis, low back pain, and dry-eye 
disease may all represent conditions with overlapping clinical and pathophysiological features 
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(i.e., those related to central sensitization), where central factors may be playing a prominent 
or exclusive role in their pathogenesis (Levitt et al., 2017; Maixner, Fillingim, Williams, Smith, & 
Slade, 2016).  Most of the initial studies examining the pathophysiology of central sensitization 
in humans have been in conditions such as FM and other COPCs, because these were amongst 
the first conditions where prominent central factors were identified.   
 
However, these same features suggesting central sensitization are also commonly seen in 
individuals with chronic pain conditions and illnesses where there is clearly ongoing nociceptive 
input.  A subset of individuals with any chronic pain condition will display features of central 
sensitization, including individuals with autoimmune disorders, any type of arthritis, cancer, 
sickle cell disease, and hypermobility syndromes (Clauw & Witter, 2009; Darbari, Ballas, & 
Clauw, 2014; Gwilym et al., 2009; Henry & Clauw, 2012; Phillips & Clauw, 2013).  Because these 
individuals with central sensitization clinically resemble individuals with FM, they were 
previously labelled as haǀiŶg ͞seĐoŶdarǇ fiďroŵǇalgia͟ in the rheumatological literature.  This 
form of central sensitization has not been nearly as well studied mechanistically in humans, in 
part because most studies of COPCs purposefully excluded individuals with demonstrable 
peripheral disease.  However, what is known about this type of central sensitization is that it 
seems to be at least in part driven by ongoing nociceptive input because, when the input is 
removed, the features of central sensitization partially or entirely remit (Gwilym, Filippini, 
Douaud, Carr, & Tracey, 2010; Kosek & Ordeberg, 2000; Staud, Weyl, Bartley, Price, & Robinson, 
2014). 
 
This present review will provide a broad overview of these aggregate studies describing the 
current understanding of central sensitization as observed in humans, as well as identify 
unresolved issues in this field. 
FEATURES OF CENTRAL SENSITIZATION GLEANED FROM EPIMEIOLOGICAL OR 
OBSERVATIONAL STUDIES  
 Individuals who develop COPCs begin developing pain and other related central-sensitization 
symptoms (fatigue, sleep disturbance, sensory sensitivity) in early life.  For example, individuals 
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who eventually go on to develop FM are more likely to experience headaches, dysmenorrhea, 
TMD, chronic fatigue, IBS and other functional GI disorders, interstitial cystitis/painful bladder 
syndrome, endometriosis, and other regional pain syndromes (especially back and neck pain) 
(Aaron & Buchwald, 2001; Hudson & Pope, 1994).  What often appears clinically as a new 
episode of acute or subacute pain is just the newest region of the body experiencing pain 
(Warren et al., 2009).  Consequently, many pain experts have suggested that COPCs are best 
understood as a single lifelong disease that merely tends to manifest in different bodily regions 
over time (Tracey & Bushnell, 2009; Williams & Clauw, 2009; Woolf, 2011). 
 
In addition to COPC, patients having a high personal lifetime history of pain, often have a strong 
family history of chronic pain.  The first-degree relatives of FM patients are eight-times more 
likely to have FM compared to family members of healthy controls, and they also report very 
high rates of other chronic pain conditions (Arnold et al., 2004).  Furthermore, family members 
of individuals with FM are much more tender than the family members of controls, regardless 
of whether they have chronic pain or not (Buskila, Neumann, Hazanov, & Carmi, 1996; Hudson, 
Hudson, Pliner, Goldenberg, & Pope, 1985; Kato, Sullivan, Evengard, & Pedersen, 2006).  This 
familial and personal co-aggregation of conditions has been called many other terms prior to 
COPCs, including affective spectrum disorder (Hudson, Goldenberg, Pope, Keck, & Schlesinger, 
1992) and, more recently, central sensitivity syndromes (Yunus, 2008), and chronic multi-
symptom illnesses (Yunus, 2008).  The key symptoms besides pain that typically co-aggregate 
together are fatigue, memory difficulties, and mood disturbances (Fukuda et al., 1997; Fukuda 
et al., 1998).  Twin studies suggest that approximately 50% of the risk of developing these 
conditions is genetic, and 50% environmental (Kato, Sullivan, Evengard, & Pedersen, 2009). 
 
Environmental factors that are associated with the development of FM and other COPCs 
include various types of ͞stressors,͟ that typically involve acute pain for at least a few weeks.  
Psychosocial stress, including childhood trauma, is but one such stressor.  FM and other COPCs 
are found at much higher than expected rates in individuals who have experienced certain 
types of infections (Buskila, Atzeni, & Sarzi-Puttini, 2008 [e.g., Epstein Barr Virus, Lyme disease, 
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Q fever, viral hepatitis]), physical trauma (e.g., motor vehicle collisions) (McLean et al., 2011), 
and deployment to war (J. D. Lewis et al., 2012).  Of note, only 5-10% of individuals exposed to 
these stressors develop FM or CFS; the overwhelming majority of individuals who experience 
these same infections or other stressful events return to their baseline state of health.  It is also 
likely that part of the reason these different stressors can seemingly lead to worsening of 
central sensitization symptoms is because of how these stressors affect activity level, sleep, or 
overall distress, any of which then can lead to worsening of pain and other symptoms (J. N. 
Ablin et al., 2013; Arnson et al., 2007; Crook, Moldofsky, & Shannon, 1998; Moldofsky, 2010; 
Moldofsky, Saskin, & Lue, 1988).  This may also be why treatments, such as exercise and 
improving sleep, seem to be so important and helpful in the overall treatment of patients with 
central sensitization.   
 
As previously noted, the central sensitization or FM-phenotype is also commonly seen as a co-
morbidity in other chronic pain conditions such as osteoarthritis, rheumatoid arthritis, and 
systemic lupus erythematosus (SLE) (Buskila, Neumann, Vaisberg, Alkalay, & Wolfe, 1997; 
Buskila, Shnaider, et al., 1997; Clauw et al., 1997; McLean & Clauw, 2004).  As many as 25% of 
patients correctly diagnosed with generalized inflammatory disorders such as SLE, rheumatoid 
arthritis, and ankylosing spondylitis will also meet the clinical criteria for FM (Clauw, 1995a, 
1995b).  This rate is even higher in individuals with conditions such as chronic low back pain, 
siĐkle Đell disease, Ehler’s DaŶlos aŶd other hypermobilitiy syndromes.  However, in clinical 
practice, this co-expression is often unrecognized, especially when central sensitization 
develops after the nociceptive or neuropathic condition is diagnosed.  In this setting, when 
comorbid central sensitization goes unrecognized, patients are often unnecessarily treated 
more aggressively with peripherally-direct interventions, such as surgery or immunosuppressive 
drugs, leading to increased morbidity without the desired therapeutic effects.  
 
FM and other COPCs occur much more commonly in individuals with early life and current 
stress, and many if not most individuals will have a lifetime history of a psychiatric disorder 
such as depression or anxiety (Epstein et al., 1999).  There is typically more psychiatric and 
Au
th
or
 M
an
us
cr
ip
t
Neurobiology of Central Sensitization 7 
 
This article is protected by copyright. All rights reserved 
psychological comorbidity seen in tertiary-care settings or in individuals who are refractory to 
treatment.  This bi-directional relationship between FM and psychiatric conditions is likely due 
in part to the fact that there are common triggers to both sets of conditions (e.g., early life 
stress or trauma), as well as shared pathophysiology (i.e., many of the neurotransmitters that 
affect pain transmission also affect mood, memory, fatigue, sleep).  Other risk factors for 
developing FM that are potentially modifiable include poor sleep, obesity, physical inactivity, 
and poor job or life satisfaction.  Similarly, cognitive factors, such as catastrophizing (the feeling 
that pain is very bad and associated with a poor prognosis for recovery) or movement-related 
fear, are poor prognostic factors in FM and other chronic pain states.  
 
Animal Models  As noted above, all of the early animal models of central sensitization required 
ongoing nociceptive input to drive central sensitization.  In fact, this was one of the hallmark 
features of central sensitization in these models, in that the observed processes seemed to 
lessen or disappear when the ongoing peripheral nociceptive input was removed or blocked.  
This led to the early view that aggressively reducing ongoing nociceptive input to block 
subsequent central sensitization (i.e., pre-emptive analgesia [Woolf, 1991]) might be useful 
therapeutically.  This general approach is still used, especially in perioperative medicine, where 
studies generally show that individuals with lower pain scores during the acute painful episode 
have less subsequent features of central sensitization following surgery (although it is often 
difficult to disentangle cause vs. effect in these studies, because individuals with less central 
sensitization would be expected to have less pain to an acute stimulus).   
 
However, more recent animal models of both somatic and visceral pain emphasize that these 
same features of central sensitization can occur without any ongoing nociceptive input.  For 
example, although few would purport that there is an animal model that mimics all of the key 
clinical features of FM, animal models can nonetheless be very helpful in understanding the 
pathogenesis of this condition (Sluka, 2009; Sluka & Clauw, 2016).  Animals can clearly develop 
the critical features of central sensitization without any ongoing nociceptive input, including 
when exposed to sub-chronic swim stress (Suarez-Roca et al., 2006); neonatal separation from 
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their mothers (Pierce & Christianson, 2015); and many other non-painful stimuli (DeSantana, da 
Cruz, & Sluka, 2013; Sluka, Kalra, & Moore, 2001).  Features of central sensitization and animal 
pain-like behaviors consistent with diffuse pain are also seen when central nervous system 
(CNS) neurotransmitters are purposefully altered in the directions found in FM.  For example, 
chronic reserpine administration (which depletes bioamines) leads to features consistent with 
central sensitization (Taguchi et al., 2015), as does directly increasing glutamate levels in the 
insulae (Watson, 2016).  This latter model of increasing insular glutamate was recently reverse-
traŶslated to shoǁ that the fiŶdiŶgs of ͞sŵall fiďer ŶeuropathǇ͟ Đould even be induced simply 
by increasing CNS glutamate, as is known to occur in FM (Harte et al., 2017). 
 
Genetic Factors  The strong familial predisposition to FM and other chronic pain conditions has 
led many to study specific genetic polymorphisms that may be associated with a higher risk of 
developing FM.  First, candidate-gene studies showed that genetic findings, such as the 
serotonin 5-HT2A receptor polymorphism T/T phenotype; serotonin transporter; dopamine 4 
receptor; and COMT (catecholamine o-methyl transferase) polymorphisms all were noted at 
higher-frequency in FM patients than controls.  Some subsequent studies confirmed certain of 
these associations, whereas others did not (Buskila, Sarzi-Puttini, & Ablin, 2007; Diatchenko, 
Fillingim, Smith, & Maixner, 2013).  Subsequent larger genome-wide linkage and candidate-
gene studies identified other putative targets (Arnold et al., 2013; Smith et al., 2012).  The 
linkage studies confirmed the strong genetic contribution to FM, and suggested linkage of FM 
to the chromosome 17p11.2-q11.2 region. The large candidate gene study identified three 
genes -- (GABRB3 [rs4906902, p = 3.65x10[-6]); TAAR1 (rs8192619, p = 1.11x10[-5]); and GBP1 
(rs7911, p = 1.06x10[-4]) with single nucleotide polymorphisms (SNPs) -- that differed in 
frequency between FM patients and healthy controls (Smith et al., 2012).  TAARI, along with 
several additional genes (RGS4, CNR1, and GRIA4) showed evidence of association with FM in a 
replication analysis using a second independent cohort of FM patients (Smith et al., 2012).  In 
light of the fact that classic genetic studies have not yet identified strong, reproducible 
polymorphisms or haplotypes associated with FM, and because there is clear evidence of 
environmental factors (such as stress) playing a prominent role in the pathogenesis, other 
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groups have postulated that epigenetic findings might be important in FM (Ciampi de Andrade 
et al., 2017).  This is a promising area that needs further research.  
 
QST EVIDENCE OF CNS DISTURBANCES IN PAIN AND SENSORY PROCESSING 
The physiological hallmark and defining feature of central sensitization is altered CNS pain-
processing.  This was originally identified clinically in conditions such as FM and TMD by 
identifying tenderness to palpation.   Following these early clinical observations, many groups 
have used much more sophisticated QST methods to identify and characterize pain and sensory 
mechanisms in individuals suspected to have central sensitization (Arendt-Nielsen, 2015; 
Arendt-Nielsen & Yarnitsky, 2009; Backonja et al., 2013; Cruz-Almeida & Fillingim, 2014; 
Edwards, Sarlani, Wesselmann, & Fillingim, 2005; Greenspan et al., 2013; Pfau, Geber, Birklein, 
& Treede, 2012; Wylde et al., 2017).  QST refers to procedures in which quantifiable stimuli 
(e.g., mechanical, thermal, or electric) are delivered in a systematic manner to the body.  An 
iŶdiǀidual’s reaction to these stimuli, including non-verbal behavioral responses, such AS 
withdrawal, ratings of perceived stimulus intensity and unpleasantness, and physiological 
responses, are used to measure sensory gain or loss.  Data from QST studies suggest a wide, 
bell-shaped distribution in pain sensitivity across the general population.  Most, but not all, 
individuals with COPCs, and a subset of individuals with any other chronic pain condition, will 
typically fall on the right side of the curve, with significant diffuse hypersensitivity outside the 
region of injury (i.e., secondary hyperalgesia and allodynia) (K. Ablin & Clauw, 2009; Diatchenko 
et al., 2006; Fillingim, 2005; Gwilym et al., 2009; Kleinbohl et al., 1999; Neddermeyer, Fluhr, & 
Lotsch, 2008; Nielsen, Staud, & Price, 2009; Tracey & Bushnell, 2009; Williams & Clauw, 2009).  
Importantly, this hypersensitivity can be present in both painful/symptomatic, as well as pain-
free/non-symptomatic body sites, which strongly suggests a central pain mechanism.  Some of 
the chronic pain conditions where widespread hyperalgesia/allodynia is consistently identified 
include FM, IBS, TMD, low back pain, tension headache, chronic pelvic pain, and vulvodynia (As-
Sanie et al., 2013; Clauw & Chrousos, 1997; Gibson et al., 1994; Giesecke et al., 2004; 
Greenspan et al., 2011; Grinberg, Granot, Lowenstein, Abramov, & Weissman-Fogel, 2017; 
Leffler, Hansson, & Kosek, 2002; Petzke, Harris, Williams, Clauw, & Gracely, 2005; Whitehead et 
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al., 1990; O. H. G. Wilder-Smith, Tassonyi, & Arendt-Nielsen, 2002). 
 
The efficiency of endogenous pain modulation networks is another marker of altered CNS pain 
processing measured by QST.  Endogenous pain inhibitory networks can be activated in humans 
aŶd aŶiŵals duriŶg appliĐatioŶ of a Ŷoǆious ͞ĐoŶditioŶiŶg͟ stiŵulus, resultiŶg iŶ atteŶuatioŶ of 
pain produced by a Ŷoǆious ͞test͟ stiŵulus applied to a different body location -- an effect 
termed conditioned pain modulation (CPM).  Although deficient CPM (i.e., reduced inhibition of 
test stimulus evoked pain) or even facilitation of test stimulus pain has been observed in a 
subset of healthy individuals (Potvin & Marchand, 2016; Schoen et al., 2016), it is more 
common in individuals with FM and other COPCs (Granot et al., 2008; Julien, Goffaux, 
Arsenault, & Marchand, 2005; Kosek & Ordeberg, 2000; Le Bars, Dickenson, & Besson, 1979; 
Mahomedy, Downing, Jeal, & Coleman, 1976; Nir & Yarnitsky, 2015; C. H. Wilder-Smith & 
Robert-Yap, 2007; Yarnitsky et al., 2008).  In fact, a 2012 meta-analysis confirmed that CPM is 
attenuated in the majority of chronic pain conditions (Lewis, Rice, & McNair, 2012).  Decreased 
CPM is associated with a variety of clinical outcomes, including increased post-surgical pain and 
analgesia requirements, and the effectiveness of some centrally-acting analgesics (Edwards, 
2005; Yarnitsky, 2015; Yarnitsky et al., 2008; Yarnitsky, Granot, Nahman-Averbuch, Khamaisi, & 
Granovsky, 2012).  Functional neuroimaging studies have begun to reveal a network of cortical 
and brainstem regions involved in the normal CPM response in humans (Bogdanov et al., 2015; 
Piche, Arsenault, & Rainville, 2009; Sprenger, Bingel, & Buchel, 2011; Youssef, Macefield, & 
Henderson, 2016a, 2016b) that is consistent with earlier studies of endogenous analgesia in 
animals, and recently we identified an aberrant pattern of PAG-to-brainstem connectivity that 
may play a role in deficient CPM, or enhanced descending facilitation, in central sensitization 
(Harper, Ichesco, Schrepf, Hampson, et al., 2018). 
 
Whereas CPM methods probe for the absence or impairment of inhibitory mechanisms, 
temporal summation of pain measures the amplification of nociceptive signaling related to 
central sensitization.  Experimentally, temporal summation refers to an increase in the 
perceived intensity of pain in response to sequential stimuli of equal physical strength.  This 
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response is thought to reflect the progressive increase in neuronal firing of dorsal horn neurons 
in response to repetitive C-fiber stimulation (i.e., windup) (Graven-Nielsen et al., 2000; Price, 
Mao, Frenk, & Mayer, 1994; Price et al., 2002; Staud, Vierck, Cannon, Mauderli, & Price, 2001; 
Weissman-Fogel et al., 2009); however, supraspinal mechanisms contribute to the regulation of 
this phenomenon (Cheng, Erpelding, Kucyi, DeSouza, & Davis, 2015).  Temporal summation is a 
normal response that occurs in healthy humans, but is enhanced in patients with central 
sensitization, and has been shown to predict pain outcomes (Arendt-Nielsen et al., 2010; 
Maixner, Fillingim, Sigurdsson, Kincaid, & Silva, 1998; Sarlani, Grace, Reynolds, & Greenspan, 
2004; Staud, Craggs, Perlstein, Robinson, & Price, 2008; Weissman-Fogel et al., 2009).  For 
example, patients with osteoarthritis that report chronic pain after joint replacement surgery 
have significantly higher temporal summation pre-operatively and post-operatively, compared 
to patients that experience pain relief (Izumi, Petersen, Laursen, Arendt-Nielsen, & Graven-
Nielsen, 2017; Petersen, Arendt-Nielsen, Simonsen, Wilder-Smith, & Laursen, 2015; Skou et al., 
2013). This suggests that enhanced temporal summation may be a marker for vulnerable 
individuals with central sensitization that respond poorly to peripherally-directed pain 
interventions.  CPM and temporal summation paradigms can also be used in combination to 
better characterize the balance of pro- and anti-nociceptive processing within individuals 
(Petersen, Graven-Nielsen, Simonsen, Laursen, & Arendt-Nielsen, 2016; Vaegter & Graven-
Nielsen, 2016; Yarnitsky, Granot, & Granovsky, 2014).  Additional QST measures that may show 
altered endogenous pain modulation in patients with central sensitization include assessments 
of pain after-sensations (pain sensations that linger after cessation of painful 
stimulation)(Staud, Koo, Robinson, & Price, 2007), and offset-analgesia (a disproportionate 
reduction in perceived pain following a subtle decrease in the intensity of painful stimulation) 
(Hermans et al., 2016; Oudejans, Smit, van Velzen, Dahan, & Niesters, 2015).   
 
In addition to hypersensitivity to painful stimuli, there is accumulating evidence that many 
patients with central sensitization exhibit hypersensitivity to non-painful stimuli that bypass 
peripheral and spinal pathways.  Patients with FM demonstrate perceptual amplification of 
auditory stimuli, and rate everyday sounds as more unpleasant compared to controls (Carrillo-
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de-la-Pena, Vallet, Perez, & Gomez-Perretta, 2006; Dohrenbusch, Sodhi, Lamprecht, & Genth, 
1997; Geisser, Glass, et al., 2008; McDermid, Rollman, & McCain, 1996; Wilbarger & Cook, 
2011).  Similar findings have been observed in TMD (Hollins et al., 2009), rheumatoid arthritis 
(McDermid et al., 1996), and IBS (Berman et al., 2002; Blomhoff, Jacobsen, Spetalen, Dahm, & 
Malt, 2000).  FM patients have also been shown to have increased sensitivity to complex visual 
stress (Harte et al., 2016), light (Martenson et al., 2016), and unpleasant odors (Schweinhardt, 
Sauro, & Bushnell, 2008).  These findings, coupled with evidence that auditory and visual 
sensitivities are often correlated with pain sensitivity in these patients (Geisser, Glass, et al., 
2008; Harte et al., 2016), have led us and others to hypothesize that a generalized or global 
state of CNS sensory amplification may play a role in the pathogenesis of chronic pain disorders, 
and that these sensory measures may mark an important individual patient endophenotype of 
central sensitization (Geisser, Donnell, et al., 2008; Hollins et al., 2009; McDermid et al., 1996).  
In fact, we propose that this might be one fundamental neurobiological difference between 
chronic pain patients with さtop-downざ central pain mechanisms, where increased sensitivity to a 
range of painful and non-painful sensory stimuli is present, and those with さbottom-upざ central 
pain mechanisms, traditionally referred to as central sensitization, where only pain processing 
might be augmented.  This is supported by the fact that functional imaging studies find that the 
insula, a brain region that also plays a role in multisensory integration, is hyperactive in most 
individuals with central sensitization (Brooks & Tracey, 2007; Wager et al., 2013).   
 
Brain Imaging Studies.  The observation that QST outcomes in individuals with FM showed 
diffuse tenderness has led to subsequent brain neuroimaging studies that have been amongst 
the ďest ͞oďjeĐtiǀe͟ eǀideŶĐe that the paiŶ iŶ FM and related-pain  syndromes are ͞real,͟ aŶd 
that the brain is playing a prominent role in pain pathophysiology (Harris & Clauw, 2006). 
 
Early studies demonstrated increased neuronal activity in CNS sensory-processing regions in 
patients with central sensitization exposed to sensory stimuli that healthy individuals find 
innocuous (Cook et al., 2004a; Gracely et al., 2004; Gracely, Petzke, Wolf, & Clauw, 2002a; 
Hampson et al., 2013; Naliboff et al., 2001).  More recent neuroimaging studies provide further 
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insight into the underlying CNS changes in central sensitization, and demonstrate significant 
structural, chemical, and functional alterations in pain-related brain areas.  As a broad 
overview, changes in brain-gray matter are noted in pain-processing regions such as: the 
thalamus; periaqueductal gray (PAG); insula; cingulate and somatosensory cortices (Smallwood 
et al., 2013); neurochemical alterations, including increased levels of excitatory 
neurotransmitters (e.g., glutamate) and decreased levels of inhibitory neurotransmitters (e.g., -aminobutyric acid [GABA] are present in the insula (Harris & Clauw, 2012); and increased 
resting brain network connectivity to pro-nociceptive brain areas; and decreased connectivity 
to anti-nociceptive brain areas are also often present in central sensitization (Ichesco et al., 
2014; K. B. Jensen et al., 2009; Loggia et al., 2013; Napadow, Kim, Clauw, & Harris, 2012).  As 
such, multiple brain neuroimaging studies have found alterations in supraspinal pain processing 
in individuals with clinical features suggestive of central sensitization. 
 
Functional magnetic resonance imaging (fMRI), in conjunction with QST, has been used to 
further demonstrate that patients with central sensitization exhibit a supraspinal-mediated 
multisensory hypersensitivity.  We recently found that the insula was activated by an aversive 
visual stimulus, and that the degree of activation was strongly associated with patients’ self-
reported FM pain (Harte et al., 2016).  Moreover, this activity within the insula was reduced 
following administration of pregabalin (but not placebo), and the analgesic effectiveness of this 
drug ǁas assoĐiated ǁith a ĐoŶĐoŵitaŶt reduĐtioŶ iŶ the iŶsula’s respoŶse to the ǀisual 
stimulus.  In addition to sensitivity to visual stimuli, methods such as fMRI clearly demonstrate 
that individuals with FM display increased brain activity when given a mild pressure or heat 
stimulus that ŵost iŶdiǀiduals ǁould feel as ͞touĐh͟ or ͞ǁarŵth,͟ rather thaŶ ͞paiŶ͟.  During 
this experience of pain, similar brain activation patterns arise in the patients that are typically 
seen in pain-processing regions that normal pain free individuals experience during a noxious 
stimulus (Cook et al., 2004b; Gracely, Petzke, Wolf, & Clauw, 2002b).  This indicates that 
individuals with central sensitization have a similar brain response to painful stimuli as controls, 
but at lower levels of stimulus intensity. 
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A more recent advance in fMRI research is to examine the extent that brain regions are 
͞ĐoŶŶeĐted͟ to eaĐh other (i.e., simultaneously activated [or deactivated] (Ploner, Lee, Wiech, 
Bingel, & Tracey, 2010), simply at rest.  The advantage of these types of resting-state analyses is 
that they provide a window into brain changes associated with chronic, ongoing spontaneous 
pain.  Individuals with FM have increased connectivity between the insula and neural networks 
not normally thought to be involved with pain, such as the Default Mode Network (DMN), and 
the degree of this hyper-connectedness is related to the severity of ongoing pain (Napadow et 
al., 2012; Napadow et al., 2010).  A different group has shown that, during a painful stimulus, 
connectivity is decreased between key anti-nociceptive regions (e.g., the brainstem – the origin 
of descending analgesic pathways) and a region they previously identified to be a potential 
source of dysfunctional pain inhibition in FM (K. B. Jensen et al., 2009; K. B. Jensen et al., 2012).  
Similar to the studies of visual stimulation described above, Lopez-Sola and colleagues 
demonstrated that individuals with central sensitization are more sensitive to a number of non-
painful sensory stimuli, and that machine-learning paradigms can accurately distinguish FM 
from non-FM patients with over 90% accuracy using fMRI results (Lopez-Sola et al., 2014; 
Lopez-Sola et al., 2017). 
 
Other neuroimaging techniques have been used to identify neurotransmitter and receptor 
abnormalities that may be driving the pain amplification seen in FM and other central 
sensitization pain disorders.  Wood and colleagues used positron emission tomography (PET) to 
show that attenuated dopaminergic activity may be playing a role in pain transmission in FM, 
and we showed evidence of decreased mu opioid receptor availability (possibly due to an 
increased release of endogenous mu opioids) in FM (Harris et al., 2007; Wood et al., 2007).  
Recent work by Schrepf and colleagues used multi-modal fMRI-PET to demonstrate that this 
reduction in opioid receptor-binding is related to reduced antinociceptive brain responses in 
the anterior cingulate cortex – providing further support for a potential endogenous opioid 
mechanism in pain central sensitization (Schrepf et al., 2016).  This latter finding, as well as 
previous studies showing increased levels of endogenous opioids in the cerebrospinal fluid 
(CSF) of FM patients (Baraniuk, Whalen, Cunningham, & Clauw, 2004), have been suggested as 
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evidence of why opioid analgesics appear to have poor efficacy in FM.   
 
Our group and others have used proton spectroscopy (
1
H-MRS) to probe other 
neurotransmitters, including glutamate and GABA.  These studies have shown increases in brain 
concentrations of glutamate in pain-processing regions, such as the insula in FM (Harris, 2010; 
Harris et al., 2009; Harte, Clauw, Napadow, & Harris, 2013; Pyke, Osmotherly, & Baines, 2017).  
This finding has also been noted in the CFS of FM patients (Sarchielli, Di Filippo, Nardi, & 
Calabresi, 2007).  Drugs that improve FM pain, such as pregabalin and gabapentin, are 
hypothesized to be working in part by reducing glutamatergic activity in the brain (Maneuf, 
Hughes, & McKnight, 2001).  In support of this, we demonstrated that baseline glutamate levels 
and functional connectivity of the insula predicted which FM patients would successfully 
respond to pregabalin therapy (Harris et al., 2013).  Patients with higher posterior insular 
glutamate and insular connectivity to the DMN had the most improvement in pain and 
hyperalgesia following pregabalin.  Furthermore, improvement in pain was accompanied by 
normalization of the glutamate and functional connectivity findings, demonstrating that these 
abnormalities were at least partly responsible for pain pathogenesis (Harris et al., 2013).  We 
have similarly shown that decreased connectivity to antinociceptive brain regions, such as the 
periaqueductal gray (PAG – a critical locus of descending analgesic pathways), predicts 
responsiveness to milnacipran, a serotonin norepinephrine reuptake inhibitor (Schmidt-Wilcke 
et al., 2014).   
 
Conversely, 
1
H-MR“ has ďeeŶ used to deŵoŶstrate loǁ leǀels of oŶe of the ďodǇ’s ŵajor 
inhibitory neurotransmitters (GABA; Foerster et al., 2012; Harper, Ichesco, Schrepf, Halvorson, 
et al., 2018), and this likely accounts for the efficacy of medications such as gamma-
hydroxybutyrate in FM (Russell et al., 2011).  This finding may also suggest biological plausibility 
for the association between low-moderate alcohol consumption (compared to none or heavy 
drinking), and improved symptomatology and functionality in FM (C. H. Kim et al., 2013; Scott 
et al., 2018).  Alcohol enhances inhibitory GABAergic neurotransmission (Chandler, Overton, 
Ruedi-Bettschen, & Platt, 2017; Chastain, 2006) and may exhibit a U-shaped curve for its 
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analgesic effects similar to its potentially beneficial cardiovascular effects.  That imbalances 
between excitatory and inhibitory neurotransmitters are not found diffusely throughout the 
brain and, instead, appear to be localized to regions that contribute to multisensory processing 
(e.g., insula) (Brooks & Tracey, 2007; Craig, 2002), is consistent with the notion that a global 
sensory hyper-responsiveness is partly responsible for the pathophysiology of FM and related 
COPCs (K. Ablin & Clauw, 2009; Yunus, 2007).  Figure 1 illustrates the neurotransmitters that 
have been demonstrated to influence pain transmission in the CNS.  This neurochemical profile 
helps illustrate why no single class of CNS analgesic is likely to work in every patient with pain of 
CNS origin. 
------------------------------------------- 
INSERT FIGURE 1 ABOUT HERE 
------------------------------------------- 
fMRI has also proven useful in determining how comorbid psychosocial factors influence pain 
processing in FM.  For example, in FM patients with variable degrees of comorbid depression, 
anterior insula and amygdala activations were correlated with depressive symptoms, consistent 
ǁith these ͞ŵedial͟ aŶd pre-frontal brain regions being involved with affective or motivational 
aspects of pain processing (and being more closely related to unpleasantness, rather than the 
sensory intensity of pain) (Berna et al., 2010).  However, the degree of neuronal activation in 
more lateral structures generally thought to be associated with the sensory-processing of pain 
(i.e., location and intensity of the pain) were not associated with levels of depressive 
symptoms, or the presence or absence of major depression. This is consistent with substantial 
evidence that pain and depression are largely independent, but overlapping, physiological 
processes.  
 
The role of neuroendocrine or autonomic abnormalities.  Because of the link between COPCs 
and exposure to stress, and because both the neuroendocrine and autonomic nervous systems 
could cause many of the symptoms of these conditions, these factors have been fairly 
extensively studied, especially in FM and CFS (Clauw & Crofford, 2003; Crofford, 1998; 
Demitrack & Crofford, 1998).  However, this research has generally yielded inconsistent 
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findings, and treatment studies targeting these systems have failed (Adler, Kinsley, Hurwitz, 
Mossey, & Goldenberg, 1999; Cohen et al., 2000; Crofford et al., 1994; Demitrack & Crofford, 
1998; Martinez-Lavin, Hermosillo, Rosas, & Soto, 1998; Qiao, Vaeroy, & Morkrid, 1991).  These 
studies note either hypo- or hyper-activity of both the hypothalamic pituitary adrenal axis (HPA) 
and sympathetic nervous system in individuals with FM and related conditions, and the precise 
abnormality varies from study to study.  Moreoǀer, these studies oŶlǇ fiŶd ͞aďŶorŵal͟ HPA or 
autonomic function in a very small percentage of patients, and there is tremendous overlap 
between cases and controls in any of these studies.  Taken together, these factors are now 
generally thought to play some role in a subset of individuals, but not in all individuals with 
these conditions.  
 
The inconsistency of these findings may be explained by the fact that nearly all of these studies 
were cross-sectional and assumed that, if HPA and/or autonomic dysfunction was found in 
these conditions, it must have caused the pain and other symptoms.  Data now suggest the 
opposite.  As noted above, more convincing data suggest that these factors (especially HPA 
abnormalities) might represent a diathesis or be due to pain or early life stress, rather than 
causing it.  Notably, in two studies examining HPA function in FM, McLean and colleagues 
showed that salivary cortisol levels covaried with pain levels, and that CSF levels of 
corticotropin-releasing factor (CRH) ǁere ŵore ĐloselǇ related to aŶ iŶdiǀidual’s paiŶ leǀel or a 
history of early-life trauma than whether they were a FM patient or control (McLean et al., 
2005; McLean et al., 2006). Because most previous studies of HPA and autonomic function in 
FM failed to control for pain levels, a previous history of trauma, or other comorbid disorders 
that could affect HPA or autonomic dysfunction, these inconsistencies are not surprising. 
 
 
Evidence of abnormal cytokines and immune dysfunction in central sensitization.  Although 
the prevailing view is that FM and related COPCs are not autoimmune disorders, and that 
classic anti-inflammatory agents are not of benefit in these conditions, there are some data 
suggesting that the immune system may be playing a role in their pathogenesis (Gur & 
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Oktayoglu, 2008).  Perhaps the most consistent finding noted to date is a mild elevation in IL-8, 
which is a cytokine associated with sympathetic function (Bazzichi et al., 2007; Wallace, 
Bowman, Wormsley, & Peter, 1989).  In other conditions closely linked to FM, such as 
interstitial cystitis, more sensitive assays of immune system function, that can be gleaned by 
stimulating peripheral immune cells, have been shown to be abnormal (Schrepf et al., 2015).  
We and others have speculated that diet or obesity could contribute to this low-grade 
inflammation in FM, and might be a potential target for therapy (Schrepf et al., 2017); while 
others have posited that this may provide evidence of microglia involvement in FM.  These 
areas warrant further exploration, and are actively being investigated.  
 
The role of ͞sŵall fiďer Ŷeuropathy͟ iŶ ĐeŶtral seŶsitizatioŶ.  Many groups have now shown 
evidence of decreased intra-epidermal nerve-fiber density (i.e., small fiber neuropathy) in FM 
(Caro & Winter, 2015; Doppler, Rittner, Deckart, & Sommer, 2015; S. H. Kim, Kim, Oh, & Clauw, 
2008; Levine & Saperstein, 2015; Oaklander, Herzog, Downs, & Klein, 2013; Uceyler et al., 
2013).  However, debate remains regarding the meaning of these findings (Clauw, 2015).  
Reduced nerve-fiber density is a very non-specific finding that has now been noted in over 50 
different pain and non-pain conditions (Clauw, 2015).  Moreover, Harte and colleagues recently 
demonstrated that these findings could be induced in an animal model of central sensitization 
by increasing insular glutamate (Harte et al., 2017).  We believe that this non-specific finding 
reflects an adaptive structural and functional reorganization of the peripheral nervous system 
(not unlike the changes in the CNS noted via voxel-based morphometry of the brain in chronic 
pain states (Smallwood et al., 2013), in the context of ongoing chronic pain and other 
neurological conditions.  The hyper-excitable C nociceptors noted in FM by Serra and colleagues 
could also be secondary to CNS disinhibition of peripheral systems, rather than indicating that 
there is primary pathology in the periphery (Serra et al., 2014). Regardless, the current 
evidence does not merit routine skin biopsies in suspected FM patients, and certainly does not 
yet suggest that this finding is of enough pathophysiological significance to support the (non-
investigational) use of aggressive cytotoxic and anti-inflammatory regimens that some have 
proposed.  When considering the available data regarding the pathophysiology of FM, including 
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the brain neuroimaging and multi-sensory hypersensitivity findings discussed above, the data 
strongly favor CNS factors rather than peripheral abnormalities, and these findings should 
continue to drive clinical care.  
 
THE CONCEPT OF CENTRAL SENSITIZATION AS A CONTINUUM – RATHER THAN PRESENT OR 
ABSENT 
Wolfe was the first to describe the concept of ͞fibromyalgianess,͟ by showing the importance 
of ͞suď-sǇŶdroŵiĐ͟ or ͞suď-threshold͟ FM (Wolfe, 2009).  In a series of studies, he showed 
that, in individuals with conditions such as rheumatoid arthritis, low back pain or osteoarthritis, 
aŶ iŶdiǀidual’s FM sĐore, deriǀed ǁith ŵeasures very similar to the 2010/11/16 American 
College of Rheumatology (ACR) FM criteria (Wolfe et al., 2016; Wolfe et al., 2011; Wolfe, Clauw, 
et al., 2010), was typically more predictive of pain and disability than more objective measures 
of activity of these illnesses, such as measures of inflammation or joint damage (Wolfe et al., 
2014; Wolfe, Michaud, Li, & Katz, 2010).  The survey version of these criteria, designed for 
clinical and epidemiological research, is entirely patient self-report, and can be administered on 
a single piece of paper (Wolfe et al., 2011).  Our group uses the Michigan Body Map (C. M. 
Brummett et al., 2016) to assess the Widespread Pain Index (up to 19 body areas each counted 
as 1-point), as well as the Symptom Severity Index that queries the presence and severity of 
fatigue, sleep disturbances, memory difficulties (each scored 0-3 for presence and severity), as 
well as irritable bowel, headaches and mood problems (1-point each; total Symptom Severity 
Index Score = 0-12; Figure 2).  The Widespread Pain Index and Symptom Severity Index are 
combined for a total FM score of 0-31.  When employed as a dichotomous measure with a 
ǀarietǇ of ͞Đut poiŶts͟ that ĐaŶ ďe used, this ŵeasure ǁill roughlǇ ideŶtifǇ ŵost of the saŵe 
individuals as the original tender point-based 1990 FM criteria (except with many more males) 
(Wolfe et al., 2011; Wolfe, Clauw, et al., 2010).  However, when FM is considered more as a 
physiological construct to determine where on the continuum of central sensitization an 
individual is, then this score can be used as a continuous measure (i.e., reflecting the degree of 
fibromyalgianess or central sensitization) that can be useful in the diagnosis and treatment of 
virtually any patient with a rheumatic disorder that is experiencing pain (Wolfe, 2009).   
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------------------------------------------- 
INSERT FIGURE 2 ABOUT HERE 
------------------------------------------- 
 
The FM score was recently shown to be associated with diffuse hyperalgesia on QST in females 
with knee osteoarthritis (Neville et al., In Press), and an index of widespread pain was used to 
identify aberrant brain structure and connectivity in pelvic pain patients with interstitial cystitis 
that was indistinguishable from women with FM (Kutch et al., 2017).  Furthermore, a recent 
fMRI study by Basu and colleagues has shown that perhaps the most consistently-found feature 
of central sensitization in COPCs - increased connectivity between the DMN and the insula - was 
also found to correlate strongly with the degree of FM that is present in individuals with 
rheumatoid arthritis (Basu et al., 2018).  Importantly, these data support the notion that central 
sensitization pathology exists in non-FM pain states, and that tools such as the FM survey 
criteria provide a useful self-report measure of this construct.  
 
In several recent studies, this concept of fibromyalgianess or sub-syndromal FM has been 
shown to be very clinically important.  In these studies by Brummett and colleagues, individuals 
who were scheduled for either lower extremity joint replacement or hysterectomy completed a 
broad-battery of validated self-report measures prior to their surgery.  It was hypothesized that 
higher FM scores on the 2011 FM survey criteria (Wolfe et al., 2011) would predict increased 
opioid requirements in the inpatient admission following surgery, as well as long-term 
postsurgical pain outcomes.  Again, this measure is scored from 0-31, with a score of 13 
typically used as the diagnostic cut-off point for FM.  These studies demonstrated that, for each 
1-point increase in this measure from 0 – 31, individuals needed an adjusted 7 – 9 mg more oral 
morphine equivalents to control their pain in the first 24-48 hours following surgery, and were 
15-20% less likely to show pain improvement following surgery (Brummett et al., 2013; 
Brummett et al., 2015; Janda et al., 2015).  These findings were independent of a number of 
preoperative characteristics, including age, sex, anxiety, depression, catastrophizing, and opioid 
use.  More importantly, these findings were linear, and the same incremental increase in opioid 
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requirements and surgery non-responsiveness was observed both in individuals well below the 
threshold to diagnose FM, and in individuals exceeding this threshold.  Figure 3 shows two 
different individuals with osteoarthritis, neither of whom would meet criteria for FM, but who 
are at different points along the fibromyalgianess continuum, and shows the marked difference 
in opioid responsiveness and improvement in pain following arthroplasty that these two 
individuals would experience.  These data suggest that the degree of central sensitization 
reflected in this measure may help identify individuals in perioperative or other settings who 
are less likely to respond to peripherally-directed treatments such as surgery.   
------------------------------------------- 
INSERT FIGURE 3 ABOUT HERE 
------------------------------------------- 
 
SUMMARY AND CONCLUSION 
As the use of the term central sensitization has expanded over the past several decades, so has 
our understanding of CNS processes that may lead to this phenomenon.  Initially thought to be 
confined to the spinal cord, supraspinal mechanisms are now understood to play a significant 
role in many individuals who have this phenomenon present.  One demarcation that is 
becoming increasingly clear, but has received little attention in the pain field, is how to 
differentiate whether an individual with this process has a problem that is being driven by 
ongoing nociceptive input (i.e., the original use of the term), or whether this process is 
occurring in the absence of a peripheral driver (as seems to be occurring in many individuals 
with COPCs).  Table 1 denotes these two sub-types of central sensitization as bottom-up (i.e., 
being driven by ongoing nociceptive input, and presumably found in individuals with 
autoimmune disorders, sickle cell disease, hypermobility syndromes), or top-down (i.e., where 
the primary problem may very well likely originate in supraspinal structures and does not 
require ongoing nociceptive input to maintain the process).  The Table reviews what we now 
know about these two sub-types, but this is an area that requires much more investigation.  
The clinical reason for differentiating these two sub-types of altered CNS processing of pain 
should be obvious – the bottom-up form should be treated aggressively with interventions 
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aimed at reducing peripheral nociceptive drive, whereas CNS-directed therapies will be 
necessary for the top-down form.  As our understanding of these two subtypes evolves, so 
should our sematic terms, and these authors suggest that the term central sensitization is only 
used to denote the bottom-up form, and a new term (e.g., central hypersensitivity) be used to 
denote the top-down form.  We further propose that, taken together, both forms constitute a 
broader clinical ĐoŶstruĐt of ͞ĐeŶtralized paiŶ͟ that exists as a continuum across individuals 
with chronic pain.  Many individuals with centralized pain are likely to have combinations of 
these two processes, and will need to be treated with both peripherally- and centrally-directed 
therapies. 
------------------------------------------- 
INSERT TABLE 1 ABOUT HERE 
------------------------------------------- 
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Figure 1.  Neurotransmitter systems that generally facilitate (left side) or inhibit (right side) 
central nervous system (CNS) pain transmission.  The arrows indicate the levels of these 
neurotransmitters in the CNS of individuals with fibromyalgia (FM), and the boxes indicate 
drugs that have been shown to be effective in FM that are likely working in part via those 
neurotransmitters.   
 
 
Figure 2.  The 2011 Survey Criteria for Fibromyalgia (Wolfe et al., 2011) using the Michigan 
Body Map (C. M. Brummett et al., 2016). 
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Figure 3.  Fibromyalgianess (FMness) scores from individuals undergoing lower extremity 
arthroplasty for osteoarthritis.
227,228
  The red line indicates the score that is used to classify an 
individual as being FM positive.  Two different hypothetical participants, who do not meet 
criteria for FM, are compared with respect to the amount of opioids(in oral morphine 
equivalents) required for pain control during a 24-48 hour inpatient period and the likelihood of 
achieving 50% improvement in pain at six months following surgery.   
 
 
 Au
th
or
 M
an
us
cr
ip
t
Neurobiology of Central Sensitization 53 
 
This article is protected by copyright. All rights reserved 
 
 
Table 1.  DiffereŶĐes ďetǁeeŶ ͞top down͟ aŶd ͞bottom up͟ forŵs of ĐeŶtral seŶsitizatioŶ.  
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Brummett CM et al. Unpublished data
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with localized pain and no 
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Patient B would need 
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Top	down	
Chronic	Overlapping	Pain	
Conditions	
Bottom	up	
Central	Sensitization
Resolves	when	
nociceptive	input	
removed
No Yes
Sex	ratio Female>>Male Female>Male
Age	of	onset	of	pain Young	– typically	following	
puberty
Any	age	when	ongoing	
nociceptive	input	occurs
Family	history	of	pain Yes No
Psych	co-morbidity High Moderate
Increased	sensitivity	to	
non-pain	sensory	
stimuli
Yes	 No
High	number	of	
functional	somatic	
syndromes	
Yes No
Clauw DJ. Refresher Courses, 16th World Congress on Pain. 2016.
Au
th
or
 M
an
us
cr
ip
t
